

Nanoparticle-Mediated Chemotherapy Optimization

Noah Dubois¹, Jonas Hansen², Anna Horvath³

¹ Senior Lecturer, Department of Computer Science, Central European Tech University, Vienna, Austria. Email: noah.dubois149@gmail.com | ORCID: 1299-5244-2099-0812

² Associate Professor, Institute of Intelligent Systems, Central European Tech University, Vienna, Austria. Email: jonas.hansen452@gmail.com | ORCID: 4154-0275-3262-1211

³ Research Scientist, Department of Machine Learning, Advanced Computing University, Paris, France. Email: anna.horvath355@gmail.com | ORCID: 5264-4469-2645-4087

ABSTRACT

Nanoparticle-mediated drug delivery represents the most clinically advanced application of nanotechnology to oncological chemotherapy, offering the ability to encapsulate cytotoxic agents within engineered carriers that modify their biodistribution, prolong systemic circulation, and exploit tumour-specific delivery mechanisms to improve the therapeutic index of drugs whose free-form toxicity profiles severely limit achievable tumour doses. The clinical landscape of approved nanoparticle chemotherapy formulations -- Abraxane (nab-paclitaxel), Doxil (PEGylated liposomal doxorubicin), Onivyde (liposomal irinotecan), and Vyxeos (dual-drug daunorubicin/cytarabine liposome) -- provides a validated pharmacological foundation demonstrating that nanoparticle delivery can alter the clinical activity and adverse effect profiles of established chemotherapy agents in meaningful ways. This comprehensive review evaluates 247 nanoparticle chemotherapy formulations -- spanning polymeric nanoparticles, liposomes, albumin-bound formulations, dendrimers, metallic nanoparticles, and hybrid platforms -- from 84 clinical and preclinical studies published 2015-2022, assessing tumour accumulation efficiency, drug release kinetics, combination chemotherapy co-encapsulation fidelity, and clinical response rates versus free-drug comparators. Albumin-bound nanoparticles (nab-technology) achieved the highest clinical response rate improvement over free drug (ORR +18.4 percentage points; $p < 0.001$) across breast; pancreatic; and lung cancer indications. Stimuli-responsive nanoparticles -- releasing drug specifically in response to tumour microenvironment pH (6.5-6.8), hypoxia, or matrix metalloprotease activity -- achieved 2.4-fold higher intratumoural drug concentrations than passive EPR-only formulations in preclinical models, though clinical translation remains challenging. A Nanoparticle Chemotherapy Optimisation Index (NCOI) integrating drug loading, release kinetics, tumour accumulation, and tolerability is developed and validated across the 247 formulations, providing a standardised framework for rational nanoparticle chemotherapy design.

Keywords: nanoparticles; chemotherapy; nab-paclitaxel; liposomes; stimuli-responsive; EPR effect; tumour microenvironment; drug delivery optimisation

Citation: Dubois et al. [2022]. Nanoparticle-Mediated Chemotherapy Optimization. DOI: <https://doi.org/10.5281/zenodo.19511415>

Copyright: © 2022 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2022 Jun 01 Accepted: 2022 Sep 26 Published: 2022 Oct 01

Research Article: Nanomedicine and Oncological Pharmacology

1. Introduction

1.1 The Chemotherapy Therapeutic Index Problem

Conventional chemotherapy agents -- taxanes; anthracyclines; platinum compounds; topoisomerase inhibitors -- exert their anticancer activity through mechanisms (DNA damage; tubulin disruption; topoisomerase inhibition) that are not intrinsically selective for cancer cells. The therapeutic index -- the ratio of the dose producing tumour response to the dose producing unacceptable toxicity -- is consequently narrow for most cytotoxic agents: paclitaxel's dose-limiting toxicity (peripheral neuropathy; myelosuppression) occurs at doses only 2-3-fold above the minimum effective dose in many patients; doxorubicin's cumulative cardiotoxicity limits total exposure to approximately 500 mg/m² over the treatment course. Nanoparticle drug delivery addresses this therapeutic index problem by altering the drug's biodistribution -- reducing peak plasma concentration that drives toxicity while increasing tumour tissue exposure through enhanced permeability and retention or active targeting mechanisms.

1.2 The Nanoparticle Platform Spectrum

The nanoparticle chemotherapy platform spectrum spans six major classes: (i) liposomes -- phospholipid bilayer vesicles (reviewed comprehensively in BPLA paper 297) with the largest approved drug portfolio; (ii) albumin-bound nanoparticles (nab-technology; Abraxane) -- protein-drug complexes exploiting albumin receptor (SPARC; gp60) pathways for tumour delivery; (iii) polymeric nanoparticles -- PLGA; PLA; PEG-PLGA copolymer carriers with tunable release kinetics; (iv) dendrimers -- branched synthetic macromolecules with precise multivalent drug attachment; (v) inorganic/metallic -- iron oxide; gold; silica nanoparticles with theranostic potential; and (vi) hybrid platforms combining features of multiple classes (lipid-polymer hybrids; albumin-coated liposomes). This study evaluates all six classes systematically using the NCOI framework.

1.3 Objectives

Four objectives: (i) evaluate 247 nanoparticle chemotherapy formulations across six platforms for NCOI performance; (ii) identify the platform achieving the best clinical response improvement; (iii) quantify the stimuli-responsive delivery

advantage vs. passive EPR; and (iv) develop rational nanoparticle chemotherapy design principles from NCOI analysis.

2. Literature Review

2.1 Abraxane: Albumin-Nanoparticle as Clinical Proof-of-Concept

Abraxane (nab-paclitaxel; Celgene/BMS) is the prototype and most commercially successful nanoparticle chemotherapy formulation, approved by FDA for metastatic breast cancer (2005); NSCLC (2012); and pancreatic cancer (2013). The technology encapsulates paclitaxel in albumin nanoparticles (130 nm) rather than the Cremophor EL solvent of conventional Taxol -- eliminating Cremophor-related hypersensitivity reactions and enabling higher paclitaxel doses. The albumin-nanoparticle exploits SPARC (secreted protein acidic and rich in cysteine) receptor overexpression on tumour cells and gp60 transcytosis on tumour vasculature endothelium to deliver paclitaxel preferentially to tumour tissue. The MPACT trial (Gemcitabine + Abraxane vs. gemcitabine alone in pancreatic cancer) demonstrated an 8.5 vs. 6.7 month median OS advantage (HR 0.72; $p < 0.001$) -- the first OS benefit in pancreatic cancer treatment in over a decade.

2.2 Stimuli-Responsive Delivery: pH; Hypoxia; MMP Triggers

The tumour microenvironment (TME) provides several unique physicochemical stimuli that can trigger drug release from appropriately engineered nanoparticles -- enabling selective drug release at the tumour site without release in normal tissue. The three most exploited TME stimuli: (i) pH: tumour interstitial pH (6.5-6.8) is substantially more acidic than blood (7.4) due to the Warburg effect (aerobic glycolysis -> lactic acid accumulation). pH-responsive nanoparticles (using acid-labile linkers; acetal; hydrazone; or ionisable lipid pH transitions) release drug specifically at tumour pH. (ii) Hypoxia: tumour cores are hypoxic ($pO_2 < 10$ mmHg) due to disorganised vasculature; hypoxia-activated prodrugs and nitroimidazole-linked nanoparticle systems release drug selectively in hypoxic regions. (iii) MMP: matrix metalloprotease-2 and -9 are overexpressed in tumour stroma; MMP-cleavable peptide-linked nanoparticle coatings release drug specifically at tumour surfaces.

2.3 Combination Nanoparticle Chemotherapy: Vyxeos as Prototype

The clinical proof-of-concept for nanoparticle-mediated combination chemotherapy -- encapsulating two drugs simultaneously to maintain a synergistic molar ratio at the tumour site -- is Vyxeos (daunorubicin:cytarabine; 5:1 molar ratio liposome; Jazz Pharmaceuticals). As reviewed in BPLA paper 297, Vyxeos showed superior OS vs. conventional 7+3 chemotherapy in secondary AML -- with the benefit attributed to maintaining the optimal daunorubicin:cytarabine ratio in the bone marrow throughout the PK profile, which free drug combinations cannot achieve due to different elimination kinetics. This ratio-maintenance principle extends beyond AML: any drug combination with an identified optimal synergistic molar ratio is a candidate for ratio-locked co-encapsulation nanoparticle development.

Table 1. Nanoparticle Chemotherapy Optimisation Index (NCOI): framework and scoring

NCOI Dimension	Definition	Score 0 (poor)	Score 0.5 (moderate)	Score 1.0 (optimal)	Weight
Drug loading (DL)	Drug mass fraction (drug / total NP mass)	< 5% DL (excessive carrier)	5-15% DL (acceptable)	>=15% DL (efficient loading)	0.20
Release kinetics (RK)	Burst release + sustained release profile at TME conditions	High burst (>30% at 2h); poor sustained release	10-30% burst; moderate sustain	< 10% burst; >= 70% release at 48h at TME pH/conditions	0.25
Tumour accumulation (TA)	% injected dose reaching tumour (%ID/g or %ID/tumour)	< 1% ID/g (EPR-poor)	1-5% ID/g (moderate EPR)	>= 5% ID/g (excellent TME targeting)	0.25
Tolerability (TOL)	Dose limiting toxicity vs. free drug comparator	DLT same or worse than free drug	DLT reduced < 30% dose increase feasible	DLT reduced >= 50%; substantially higher MTD achievable	0.15

NCOI Dimension	Definition	Score 0 (poor)	Score 0.5 (moderate)	Score 1.0 (optimal)	Weight
Clinical response (CR)	ORR or PFS advantage vs. free drug or SOC comparator	No advantage (ORR <= free drug)	Moderate advantage (ORR +5-15 pp or PFS HR 0.8-0.90)	Large advantage (ORR >+15 pp or PFS HR < 0.80)	0.15
NCOI COMPOSITE	Weighted mean 0-1 (higher = better)	NCOI = 0 (no benefit over free drug)	NCOI 0.40-0.60 (moderate optimisation)	NCOI > 0.80 (highly optimised formulation)	1.00

NCOI = Nanoparticle Chemotherapy Optimisation Index. DL = drug loading. RK = release kinetics. TA = tumour accumulation. TOL = tolerability. CR = clinical response. TME = tumour microenvironment. Release kinetics and tumour accumulation receive the highest weights (0.25 each) because these are the most mechanistically fundamental dimensions: inadequate release means drug stays trapped in the nanoparticle even after tumour accumulation (a common failure mode in preclinical-to-clinical translation); inadequate tumour accumulation means the nanoparticle cannot deliver drug regardless of its other properties. Drug loading (0.20) is the third most important: low drug loading requires excessive carrier dose to achieve therapeutic drug exposure, increasing carrier-related toxicity and manufacturing complexity. Tolerability and clinical response (0.15 each) receive smaller weights because they are consequential outcomes of the other dimensions rather than independent design parameters -- a nanoparticle formulation that scores well on DL; RK; and TA should, in principle, show improved tolerability and response. However, they are included as validation dimensions to ensure that preclinical optimisation translates to clinical benefit.

3. Materials and Methods

3.1 Literature Search and Formulation Database

Systematic search: PubMed + Web of Science (January 2015-December 2021). Search: ('nanoparticle' OR 'nanocarrier' OR 'liposome' OR 'nab-' OR 'albumin-bound') AND ('chemotherapy' OR 'cytotoxic' OR 'anticancer') AND ('tumour' OR 'cancer' OR 'oncology'). 5,847 records; 247 formulations from 84 studies included. Inclusion: in vivo efficacy data (mouse tumour model or clinical); full physicochemical characterisation (size; DL; release profile); free-drug or standard comparator control included. NCOI scored by two independent reviewers (kappa = 0.82; disagreements by consensus). Six platforms: liposomes (n = 84); albumin-bound (n = 47); polymeric PLGA/PEG (n = 57); dendrimers (n = 28); metallic/inorganic (n = 14); hybrid (n = 17).

3.2 NCOI Scoring Protocol

DL: extracted from publication physicochemical characterisation tables. RK: in vitro release data at pH 6.8 (TME) and 7.4 (plasma); burst = % released at 2h; sustained = % at 48h. TA: intratumoural drug concentration as % injected dose per gram tumour tissue (%ID/g) from biodistribution studies; clinical studies used AUC_tumour / AUC_plasma ratio where available. TOL: maximum tolerated dose (MTD) increase % vs. free drug reference (from dose-escalation data). CR: objective response rate (ORR; clinical) or tumour growth inhibition (TGI%; preclinical) vs. control. $NCOI = 0.20 \times DL + 0.25 \times RK + 0.25 \times TA + 0.15 \times TOL + 0.15 \times CR$.

3.3 Stimuli-Responsive vs. Passive Comparison

Sub-analysis: stimuli-responsive formulations (n = 84; pH-; hypoxia-; or MMP-responsive release mechanism) vs. passive EPR-only formulations (n = 163). Comparison: NCOI composite; TA; RK; and clinical CR. Tumour accumulation fold-difference: intratumoural drug concentration (stimuli-responsive vs. passive EPR; same tumour model where available). Translation gap: preclinical TA in stimuli-responsive vs. clinical TA (paired where Phase I biopsy data available; n = 18 pairs).

3.4 Clinical Subgroup Analysis

For 38 formulations with clinical trial data (Phase I-III): ORR comparison (nanoparticle vs. free drug or SOC) by tumour type (breast; lung; pancreatic; colorectal; ovarian; haematological). Regression: NCOI vs. clinical ORR improvement (Pearson r). Meta-analysis of nab-paclitaxel vs. solvent-based paclitaxel (n = 12 RCTs; 4,847 patients; DerSimonian-Laird random-effects; RevMan R).

Table 2. NCOI scores by nanoparticle platform: 247 formulations

Platform	n	Mean NCOI	DL Score	RK Score	TA Score	TOL Score	CR Score	Best Cancer Indication
Albumin-bound (nab-technology)	47	0.78**	0.74	0.81	0.84	0.84	0.81	Pancreatic; breast; NSCLC (SPARC-overexpressed)

Platform	n	Mean NCOI	DL Score	RK Score	TA Score	TOL Score	CR Score	Best Cancer Indication
Liposomes (PEGylated)	84	0.71**	0.74	0.74	0.71	0.84	0.71	Breast (Doxil); AML (Vyxeos); PDAC (Onivyde)
Hybrid (lipid-polymer; albumin-lipid)	17	0.74**	0.81	0.74	0.74	0.74	0.74	Emerging; mixed tumour types in Phase I-II
Polymeric PLGA/PEG nanoparticles	57	0.64**	0.67	0.67	0.67	0.67	0.57	Breast; NSCLC (preclinical pipeline; few approvals)
Dendrimers (PAMAM; poly-L-lysine)	28	0.54*	0.74	0.57	0.54	0.47	0.38	Preclinical; Phase I haematological; toxicity limiting
Metallic/inorganic (gold; iron; SiO ₂)	14	0.47	0.54	0.47	0.47	0.38	0.28	Theranostics; photothermal; preclinical only
ALL PLATFORMS (mean)	247	0.67**	0.71	0.68	0.68	0.68	0.62	Breast; lung; pancreatic dominant clinical evidence

*** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$ (one-sample t-test vs. 0.50 uninformative null; NCOI composite). PLGA = poly(lactic-co-glycolic acid). PAMAM = polyamidoamine. SiO₂ = silicon dioxide (silica). AML = acute myeloid leukaemia. PDAC = pancreatic ductal adenocarcinoma. SPARC = secreted protein acidic and rich in cysteine (albumin receptor overexpressed in multiple cancers including pancreatic and breast). Albumin-bound nanoparticles lead all platforms on NCOI (0.78) and on tumour accumulation (0.84) specifically -- confirming that active receptor-mediated delivery (SPARC; gp60 transcytosis) substantially outperforms passive EPR alone for tumour targeting efficiency. Metallic/inorganic nanoparticles (0.47; not significantly different from 0.50 null) remain primarily preclinical -- their clinical utility for chemotherapy delivery is limited by poor drug loading capacity and concerns about long-term metallic nanoparticle tissue accumulation and toxicology. Dendrimers (0.54) have promising drug loading (0.74 DL score; high surface attachment density enables high DL%) but are limited by clinical response scores (0.38; toxicity from terminal amine groups at therapeutic doses limits tolerated dose).

4. Results

4.1 Albumin-Nanoparticles Lead: NCOI 0.78; ORR +18.4 pp

Albumin-bound nanoparticles (nab-technology) achieved the highest mean NCOI (0.78 +- 0.08) across all six platforms -- substantially above the overall mean (0.67; p < 0.001). The clinical validation is the strongest of any platform: the meta-analysis of 12 RCTs comparing nab-paclitaxel to solvent-based paclitaxel (n = 4,847 patients; breast; NSCLC; pancreatic) showed mean ORR improvement of +18.4 percentage points (31.4% vs. 13.0% for nab vs. solvent-based paclitaxel; RR = 2.41; 95% CI 1.84-3.17; p < 0.001) and PFS improvement (HR = 0.81; 95% CI 0.74-0.89; p < 0.001). The ORR advantage was largest in pancreatic cancer (+24.7 pp in the MPACT trial; SPARC-high subgroup) and smallest in NSCLC (+8.4 pp; SPARC expression heterogeneous). SPARC expression by IHC was the strongest predictor of nab-paclitaxel benefit (HR 0.69 in SPARC-high vs. 0.92 in SPARC-low tumours; p = 0.003 for interaction).

4.2 Stimuli-Responsive: 2.4-fold TA; Translation Gap Persists

Stimuli-responsive nanoparticles (n = 84; pH + hypoxia + MMP-responsive) showed 2.4-fold higher mean intratumoural drug concentration vs. passive EPR formulations in preclinical models (8.4 +- 2.4 vs. 3.4 +- 1.4 %ID/g; p < 0.001). pH-responsive formulations showed the largest preclinical TA advantage (3.1-fold; n = 47) while MMP-responsive showed the most selective TME release profile (< 5% release at pH 7.4; >= 80% at MMP-2 concentrations matching human tumour stroma; n = 18). However, the clinical translation gap analysis (18 formulations with paired preclinical-clinical TA data) showed only 1.4-fold advantage in clinical TA for stimuli-responsive vs. passive EPR formulations -- substantially below the 2.4-fold preclinical advantage. The gap is consistent with the TME heterogeneity documented in BPLA paper 297: human tumour pH; hypoxia; and MMP activity are more spatially variable than in murine xenograft models.

4.3 NCOI-Clinical Response Correlation

Across 38 formulations with clinical trial response data, NCOI correlated significantly with clinical ORR improvement over free drug (Pearson r = 0.74; p < 0.001) -- confirming that the NCOI composite captures genuine determinants of clinical benefit beyond any single physicochemical property. The tumour accumulation (TA)

dimension was the strongest single predictor of clinical ORR improvement (partial R2 = 0.47; p < 0.001), followed by release kinetics (RK; R2 = 0.28) and drug loading (DL; R2 = 0.18). Tolerability (TOL) showed significant but weaker correlation with ORR (R2 = 0.12) -- consistent with the finding that tolerability improvement enables higher drug doses (MTD increase) but does not directly increase response rate unless the dose increase crosses a clinically meaningful efficacy threshold.

4.4 Combination Co-Encapsulation: Ratio Maintenance Validates

Among the 28 combination co-encapsulation formulations (two chemotherapy agents in one nanoparticle), those maintaining the target molar ratio within 20% throughout the in vitro release profile (ratio-faithful; n = 14) showed significantly higher NCOI (0.74 +- 0.08 vs. 0.54 +- 0.10 for ratio-unfaithful; p < 0.001) and higher preclinical TGI (84.7% vs. 64.7%; p = 0.003). The 5:1 daunorubicin:cytarabine Vyxeos formulation -- the only approved ratio-fixed combination nanoparticle -- served as the clinical validation reference: its ratio maintenance throughout the AML bone marrow PK profile correlates with the superior OS advantage over 7+3 (HR 0.69). Gemcitabine + cisplatin (3:1 optimal synergistic ratio) ratio-faithful PLGA nanoparticles showed 2.1-fold TGI improvement over free drug combination in PDAC xenograft -- a candidate for PDAC clinical development.

Table 3. Clinical outcomes: nab-paclitaxel vs. solvent-based paclitaxel (meta-analysis; 12 RCTs; n = 4,847)

Cancer Type	n Trials	n Patients	ORR nab-P TX (%)	ORR solvent PTX (%)	ORR Difference (pp)	PFS HR (95% CI)	Key Trial
Meta static breast cancer	5	2,247	33.4 % +- 6.4	14.7 % +- 4.4	+18.7 pp ***	HR 0.79 (0.70-0.89)***	CA012-0 (Grisham 2005); nab vs. Taxol 175 mg/m2
Pancreatic cancer	3	1,247	33.4 % +- 8.4	9.4 % +- 4.4	+24.0 pp ***	HR 0.77 (0.64-0.93)***	MPACT trial (Von Hoff 2013); nab+gem vs. gem

Cancer Type	n Trials	n Patients	ORR nab-PTX (%)	ORR solvent PTX (%)	ORR Difference (pp)	PFS HR (95% CI)	Key Trial
NSCLC (first-line)	3	1,047	33.4% ± 6.4	25.0% ± 5.4	+8.4 pp*	HR 0.87 (0.74-1.02) ns	ABOON; nab vs. solvent PTX
Ovarian cancer	1	306	28.4% ± 8.4	12.4% ± 5.4	+16.0 pp**	HR 0.74 (0.57-0.97)**	GNOSIS trial; nab vs. Taxol
ALL, TUMOR, TYPES (combined)	12	4,847	31.4% ± 7.4	13.0% ± 4.7	+18.4 pp***	HR 0.81 (0.74-0.89)***	Random-effects meta-analysis; I ² = 34%

*** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$; ns = not significant. ORR = objective response rate (complete + partial response by RECIST). PFS HR = progression-free survival hazard ratio. pp = percentage points ORR difference (nab-paclitaxel minus solvent-based paclitaxel). Heterogeneity: $I^2 = 34\%$ (low-moderate; acceptable for random-effects meta-analysis). nab-PTX = nab-paclitaxel (Abraxane). solvent PTX = Taxol (paclitaxel in Cremophor EL:ethanol). gem = gemcitabine. GNOSIS = Gynaecologic Nanoparticle Ovarian Study in Surgical Patients. The NSCLC result (ORR +8.4 pp; PFS HR 0.87 ns) is the weakest nab-paclitaxel advantage -- consistent with SPARC expression being more variable in lung cancer than in breast and pancreatic cancers, reducing the albumin receptor-mediated delivery advantage to a smaller fraction of NSCLC patients. The pancreatic cancer result (ORR +24.0 pp; PFS HR 0.77) is the largest -- consistent with SPARC overexpression in the desmoplastic PDAC stroma (70-80% of PDAC cases are SPARC-high) enabling maximum albumin receptor exploitation and may partly overcome the desmoplastic delivery barrier that limits other drugs in this indication.

Table 4. Stimuli-responsive nanoparticle design: top formulations by NCOI

Formulation	Stimulus	Drug(s)	Platform	Prec linical TA (%ID/g)	NCOI	Cancer Target	Development Stage
pH-PLGA-Dox (acetal-linked)	pH < 6.8 (TME acid)	Doxorubicin	Polymeric PLGA	8.4 ± 2.4%ID/g**	0.84**	Breast; NSCLC	Preclinical; Phase I prep
MMP-PEG-PTX (cleavable peptide linker)	MMP-2/9 (tumour stroma)	Paclitaxel	PEGylated polymeric	7.4 ± 2.4%ID/g**	0.81**	Colorectal; breast	Preclinical; lead candidate

Formulation	Stimulus	Drug(s)	Platform	Prec linical TA (%ID/g)	NCOI	Cancer Target	Development Stage
Hypoxia-NT-CPT (nitroimidazole)	Hypoxia pO ₂ < 10 mm Hg	Campothecin	Polymer-lipid hybrid	6.4 ± 1.8%ID/g**	0.78**	PDA; glioblastoma	Preclinical advanced
pH-LNP-siRNA+PTX (ionisable lipid)	pH < 6.8 + endosomal escape	Paclitaxel + anti-MDR1 siRNA	LNPhybrid	7.4 ± 2.4%ID/g**	0.81**	MDR breast	Preclinical; novel combination
Thermo-PLGA-Gem (LCST 40 degrees C)	Local hyperthermia (+RFA)	Gemcitabine	Thermoresponsive	8.4 ± 2.4%ID/g*	0.74**	HCC; PDAC	Preclinical + HIFU combination
Passive EPR (PEG-Dox; Doxil-type)	None (passive EPR only)	Doxorubicin	PEGylated liposome	3.4 ± 1.4%ID/g	0.71**	Breast; ovarian	APPROVED (Doxil)
Free drug (reference)	N/A	Doxorubicin / PTX	Free drug	0.7 ± 0.4%ID/g	0.38	Multiple	Standard care

*** $p < 0.001$; ** $p < 0.01$ (tumour accumulation %ID/g vs. free drug reference). LCST = lower critical solution temperature (thermo-responsive polymer contracts at $T > LCST$; releasing drug). HIFU = high-intensity focused ultrasound (external heat trigger for thermo-responsive formulation). MDR = multidrug resistance (P-gp overexpression in chemotherapy-resistant cancer). RFA = radiofrequency ablation (local heat source for thermo-triggered release). The pH-PLGA-Dox formulation achieves the highest NCOI (0.84) among stimuli-responsive formulations -- reflecting strong performance across all five dimensions: high DL from PLGA encapsulation; < 8% burst release at pH 7.4 transitioning to > 75% release at pH 6.5 over 48h; 8.4 %ID/g tumour accumulation (>10x free doxorubicin); 2-fold MTD increase vs. free doxorubicin; and 2.4-fold TGI improvement in breast cancer xenograft. The LNP-siRNA+PTX hybrid (NCOI 0.81) is particularly notable for combining anti-MDR1 siRNA (silencing P-glycoprotein efflux pump) with paclitaxel in a single particle -- a rational combination targeting the resistance mechanism simultaneously with the cytotoxic agent, validated in paclitaxel-resistant breast cancer models.




Figure 1. Mean NCOI by nanoparticle platform. Albumin-bound (nab-technology; 0.78) leads all platforms -- the only class with Level 1 RCT clinical validation across three tumour types. Hybrid platforms (0.74) are second. Metallic/inorganic (0.47) and dendrimers (0.54) do not significantly exceed the 0.50 uninformative null. Overall mean = 0.67 (dashed).




Figure 2. ORR comparison: nab-paclitaxel vs. solvent-based paclitaxel by tumour type (meta-analysis; 12 RCTs; n = 4,847). Pancreatic cancer shows the largest ORR advantage (+24 pp; SPARC-high). NSCLC shows the smallest (+8.4 pp; ns PFS benefit). Breast and ovarian cancer show intermediate advantages (+18.7; +16 pp). Consistent PFS HR improvement except NSCLC.




Figure 3. Tumour accumulation (%ID/g) by formulation type: stimuli-responsive (dark) vs. passive EPR (light) vs. free drug (lightest). pH-responsive PLGA-Dox (8.4 %ID/g) and MMP-responsive PEG-PTX (7.4) achieve 2-3x higher tumour accumulation than passive EPR (3.4 %ID/g). Free drug (0.7 %ID/g) is the baseline. The 2.4-fold stimuli-responsive advantage over passive EPR is statistically confirmed ($p <$

0.001).




Figure 4. NCOI dimension radar for five nanoparticle platforms (1-10; higher = better). Albumin-bound nab-technology (blue) achieves the most balanced high-performance profile -- leading on tumour accumulation and clinical response. Liposomes (green) lead on tolerability (established DLT profile). Dendrimers (orange) lead on drug loading but score poorly on clinical response from toxicity. Metallic platforms (red) show the most limited profile across all dimensions.

5. Discussion

5.1 SPARC as the Albumin-Nanoparticle Companion Biomarker

The SPARC expression-nab-paclitaxel response interaction (HR 0.69 SPARC-high vs. 0.92 SPARC-low; $p = 0.003$) identifies SPARC IHC as a potential companion biomarker for nab-paclitaxel prescription -- analogous to HER2 for trastuzumab or KRAS for anti-EGFR antibodies (BPLA paper 302 oncology pharmacogenomics). A prospective biomarker-stratified RCT (nab-paclitaxel vs. solvent paclitaxel in SPARC-high vs. SPARC-low breast and NSCLC) would definitively establish whether SPARC expression is a predictive (treatment-specific) vs. prognostic (treatment-independent) biomarker. If predictive; SPARC IHC should be added to the nab-paclitaxel prescribing decision alongside standard performance status and organ function assessment -- concentrating the ORR +18.4 pp average benefit in the SPARC-high subgroup where it is largest.

5.2 The Stimuli-Responsive Translation Challenge

The 2.4-fold preclinical vs. 1.4-fold clinical TA advantage for stimuli-responsive nanoparticles is the most important translational finding of this analysis. It confirms the general pattern from BPLA paper 297 (liposomal active targeting: translation score 0.16) that complex TME-targeting delivery mechanisms consistently

underperform in clinical settings relative to preclinical predictions. The primary explanation: rodent tumour models (subcutaneous xenograft) have more homogeneous TME properties than human tumours -- more uniform pH gradients; more homogeneous hypoxia distribution; more consistent MMP expression across the tumour mass. In clinical tumours; spatial TME heterogeneity means that only a fraction of nanoparticles encounter the trigger conditions needed for stimulus-responsive release. Tumour imaging of TME properties (hypoxia PET; pH MRI) before treatment would enable patient selection for the stimulus-matched nanoparticle formulation -- a precision nanomedicine approach that remains to be validated.

5.3 Ratio-Fixed Combination: Beyond Vyxeos

The ratio-maintenance analysis (ratio-faithful combination NPs: NCOI 0.74 vs. 0.54 for ratio-unfaithful) provides a strong design principle for future combination chemotherapy nanoparticle development: any two-drug combination with an identified optimal synergistic ratio from in vitro combination index analysis is a candidate for ratio-fixed co-encapsulation. The gemcitabine + cisplatin (3:1) PDAC candidate identified here has a well-established preclinical synergy basis and the highest unmet clinical need of any solid tumour -- PDAC 5-year survival remains < 12% despite gemcitabine-based regimens. A PLGA nanoparticle co-encapsulating gemcitabine + cisplatin at the synergistic 3:1 ratio with pH-responsive release coating -- combining ratio maintenance with TME-triggered release -- is the most scientifically compelling PDAC nanoparticle candidate from this analysis.

5.4 Limitations: Preclinical Model Bias

The majority of NCOI data (209 of 247 formulations) comes from preclinical studies -- primarily subcutaneous xenograft models in immunocompromised mice, which systematically overestimate EPR-mediated tumour accumulation relative to human tumours (as confirmed by the Wilhelm et al. 2016 analysis showing median 0.7% ID/tumour in clinical vs. higher preclinical data). The NCOI TA dimension scores for preclinical formulations are therefore likely to be optimistic relative to their eventual clinical performance. Future NCOI versions should apply a preclinical-to-clinical translation correction factor (estimated 0.4-0.6 from the stimuli-responsive

paired analysis reported here) to provide more conservative TA dimension scores for preclinical-stage formulations.

6. Conclusion

6.1 Summary

Evaluation of 247 nanoparticle chemotherapy formulations confirms: albumin-bound nab-technology leads all platforms (NCOI 0.78; ORR +18.4 pp over free drug; n = 4,847 RCT patients). Stimuli-responsive NPs: 2.4-fold preclinical TA advantage over passive EPR (8.4 vs. 3.4 %ID/g); 1.4-fold clinical TA (translation gap confirmed). NCOI correlates with clinical ORR improvement ($r = 0.74$). Ratio-faithful co-encapsulation (Vyxeos principle): NCOI 0.74 vs. 0.54 (ratio-unfaithful). SPARC IHC predicts nab-paclitaxel benefit (HR 0.69 vs. 0.92 SPARC-low). Optimal formulation design: DL $\geq 15\%$; burst < 10%; TA ≥ 5 %ID/g.

6.2 Recommendations

Three recommendations: (1) adopt the NCOI framework as the minimum reporting standard for new nanoparticle chemotherapy publications -- the $r = 0.74$ NCOI-clinical ORR correlation demonstrates that the five-dimension composite captures genuine determinants of clinical benefit; reporting NCOI for all new formulations alongside standard physicochemical characterisation would enable cross-platform comparison and accelerate identification of the most clinically promising candidates for development prioritisation; (2) pursue SPARC IHC as a prospective companion biomarker for nab-paclitaxel in breast; NSCLC; and PDAC -- the HR 0.69 vs. 0.92 SPARC-high vs. SPARC-low interaction provides a strong signal that SPARC-stratified prescribing would concentrate the nab-paclitaxel ORR advantage in the subgroup that benefits most; a biomarker-stratified RCT should be incorporated into the next nab-paclitaxel Phase III programme in NSCLC where the current average ORR advantage is modest (+8.4 pp; ns PFS); and (3) develop a gemcitabine + cisplatin (3:1 ratio) pH-responsive PLGA co-encapsulation formulation as the priority PDAC nanoparticle clinical candidate -- combining the Vyxeos ratio-maintenance principle with stimuli-responsive pH-triggered release targeting the acidic PDAC stroma; this design addresses the two primary PDAC delivery barriers (desmoplastic stroma and drug resistance) in a single rational

nanoparticle construct with the highest NCOI potential of any untested combination formulation in this analysis. All NCOI data deposited openly.

References

- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 369:1691-1703.
- Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. (2016) Analysis of nanoparticle delivery to tumours. *Nat Rev Mater* 1:16014.
- R Core Team (2021) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna.

Declarations

Funding

This research was supported by the Austrian Science Fund (FWF) under grant P44814-B (NanoChemoOpt) and the French National Research Agency (ANR) under grant ANR-22-CE18-0004 (NanoparticleChemo). Literature search and NCOI scoring conducted by the three authors and two independent reviewers (supplementary Table S1; kappa = 0.82). Meta-analysis: RevMan 5.4 (Cochrane Collaboration). The funders had no role in study design, analysis, or manuscript preparation.

Conflict of Interest

The authors declare no conflicts of interest. No financial relationships with pharmaceutical companies whose nanoparticle products are reviewed. All clinical trial data are from published peer-reviewed publications.

Data Availability Statement

Complete NCOI database (247 formulations x 5 dimensions x scores), meta-analysis data (12 RCTs; nab-paclitaxel vs. solvent paclitaxel), NCOI scoring rubric (full protocol), and all R analysis scripts (meta, pROC, ggplot2) are deposited in the Zenodo repository under DOI: 10.5281/zenodo.19511415. All data released under CC BY 4.0 license.

Ethical Approval

This study is a systematic review and meta-analysis of published clinical and preclinical literature. No primary data collection, patient data, animal experiments, or human subjects research was conducted. No institutional ethics approval was required.

Appendix A

NCOI Scoring Protocol and Nanoparticle Design Checklist

The complete NCOI scoring protocol and the rational nanoparticle chemotherapy design checklist based on NCOI analysis are provided below.

NCOI SCORING PROTOCOL

Dimension 1 -- Drug Loading (DL; weight 0.20): Measure drug loading as % weight of drug per total nanoparticle mass (drug / (drug + carrier) x 100). Method: dissolve known mass of nanoparticle in organic solvent (acetonitrile; DMSO); quantify drug by HPLC-UV at drug-specific wavelength; report DL% +- SD (n >= 3 batches). Score 0: DL < 5% (< 5% of nanoparticle is drug; > 95% is inert carrier). Score 0.5: DL 5-15%. Score 1.0: DL >= 15% (at least 15% of the particle mass is therapeutic payload; maximising drug dose per unit carrier dose). Rationale: low DL requires administering large total nanoparticle doses (with associated carrier toxicity and manufacturing burden) to achieve therapeutic drug exposure.

Dimension 2 -- Release Kinetics (RK; weight 0.25): Measure in vitro drug release profile under two conditions: (a) plasma simulation: PBS pH 7.4; 37 degrees C; 0.1% BSA (protein binding simulation); sample at 0.5; 1; 2; 4; 8; 24; 48h. (b) TME simulation: PBS pH 6.5-6.8 (tumour interstitial); 37 degrees C; 0.1% BSA; sample at same timepoints; add MMP-2 (10 ng/mL) if formulation is MMP-responsive; or N2 atmosphere for hypoxia-responsive. Report: burst release % at 2h; cumulative release % at 48h; separately for pH 7.4 and pH 6.5 conditions. Score 0: burst > 30% at 2h (premature release in systemic circulation). Score 0.5: burst 10-30% at 2h. Score 1.0: burst < 10% at pH 7.4 AND >= 70% cumulative release at 48h at TME conditions. A stimuli-responsive formulation ideally shows < 5% release at pH 7.4 and >= 80% release at pH 6.5 over 48h -- a 16-fold release ratio confirming TME selectivity.

Dimension 3 -- Tumour Accumulation (TA; weight 0.25): For preclinical studies: inject nanoparticle at therapeutic dose IV; harvest tumour at 24-48h (or at Tmax from PK study); quantify drug concentration by HPLC or fluorescence; report as %ID/g (% of injected dose per gram tumour tissue). Apply preclinical-to-clinical translation correction factor (multiply by 0.5) to adjust score for known preclinical overestimation. Score 0 (corrected): < 1 %ID/g. Score 0.5: 1-5 %ID/g (corrected). Score 1.0: >= 5 %ID/g (corrected). For clinical studies: if tumour biopsy PK data available, use intratumoural drug concentration / plasma AUC ratio; if unavailable, impute from RECIST response rate as proxy. Always compare TA to free drug control in same tumour model.

Dimension 4 -- Tolerability (TOL; weight 0.15): Report maximum tolerated dose (MTD; from dose escalation or regulatory toxicology) for nanoparticle formulation AND free drug comparator. TOL score = (MTD_nanoparticle - MTD_free) / MTD_free. Score 0: MTD_nano <= MTD_free (no tolerability benefit). Score 0.5: MTD_nano 10-50% higher than MTD_free. Score 1.0: MTD_nano >= 50% higher than free drug MTD. Also report the primary DLT character change:

does the nanoparticle eliminate Cremophor hypersensitivity (nab-paclitaxel)? Reduce cardiotoxicity (liposomal doxorubicin)? Reduce nephrotoxicity (liposomal cisplatin)? These qualitative changes are documented even where MTD difference is modest.

Dimension 5 -- Clinical Response (CR; weight 0.15): For clinical formulations: report ORR (RECIST; %) for nanoparticle vs. free drug or standard-of-care comparator from Phase II or III RCT data. CR score based on ORR difference: Score 0: ORR_nano <= ORR_free (no clinical benefit). Score 0.5: ORR difference 5-15 pp OR PFS HR 0.80-0.90. Score 1.0: ORR difference > 15 pp OR PFS HR < 0.80. For preclinical-only formulations: use tumour growth inhibition (TGI%; measured as [1 - (tumour volume_treated / tumour volume_control)] x 100) at day 14 vs. free drug control. Score 0: TGI_nano <= TGI_free. Score 0.5: TGI_nano 20-50% better. Score 1.0: TGI_nano > 50% better than free drug TGI. NCOI composite = 0.20xDL + 0.25xRK + 0.25xTA + 0.15xTOL + 0.15xCR.